Home
Juncell Therapeutics

Juncell Therapeutics Market Share Analysis for May 2026

君赛

Industry: N/A

Domainjuncell.com

Year Founded--

Employees51 - 200

Annual Revenue--

Juncell Therapeutics

Juncell Therapeutics (including company regionals)

juncell.com

See more website traffic and engagement information

Total visits to Juncell Therapeutics's top domains

Understand Juncell Therapeutics market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Juncell Therapeutics's top domains

Analyze Juncell Therapeutics engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Juncell Therapeutics's top domains

See how Juncell Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Juncell Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Juncell Therapeutics

These are the website technologies, by industry, used by Juncell Therapeutics top domains

Conversion & Analytics (2)

CNZZ

Advertising (1)

Baidu Ads

Mobile (1)

Meta Viewport

News & Signals from Juncell Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsJuncell attended event 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Jun 1st '26.SHANGHAI, June 3, 2026 /PRNewswire/ - On June 1 (Chicago time), in a Late-Breaking Abstract (LBA) oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Lu Si from Peking University Cancer Hospital presented the results of a Pivotal Phase 2 clinical study (MIZAR-003) conducted in China evaluating the efficacy and safety of GC101 TIL therapy (Nolgileucel), developed by Shanghai Juncell Therapeutics Co., Ltd. for PD-1 antibody failed patients with advanced melanoma.

NewsJuncell attends event ASGCT Annual Meeting 2025.Juncell Therapeutics announces data on feeder-free IL-2-Independent TIL manufacturing process at ASGCT Annual Meeting 2025.

NewsJuncell receives award Disruptive Technology Innovation Competition.Juncell Therapeutics wins the highest award in the national Disruptive Technology Innovation Competition sponsored by the Ministry of Science and Technology.